Coagulation for the clinician

South African Journal of Surgery

Volumn 44, Issue 1, 2006, Pages 22-37

  Ruttmann, Tom ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRIN; THROMBIN;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; HEMOSTASIS; REVIEW; THROMBOCYTE;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD PLATELETS; FEEDBACK, BIOCHEMICAL; FIBRIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLATELET ACTIVATION;

EID: 33645405000     PISSN: 00382361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Camera M et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 531-537.
2. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffmann T. Evidence for the presence of tissue factor activity on subendothelium. Blood 1989; 73: 968-975.
3. Yang HL, Lu FJ, Wung SL, Chiu HC. Humic acid induces expression of tissue factor by cultured endothelial cells: regulation by cytosolic calcium and protein kinase C. Thromb Haemost 1994; 71: 325-330.
4. Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991; 266: 11317-11327.
5. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264.
6. Luchtman-Jones L, Broze GJ jun. The current status of coagulation. Ann Med 1995; 27: 47-52.
7. Macfarlane RG. A clotting scheme for 1964. Thromb Diath Haemorrh Suppl 1965; 17: 45-52.
8. Ratnoff OD. The development of knowledge about haemostasis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. New York: Churchill Livingstone, 1994: 3-28.
9. Gallus AS, Lee LH, Coghlan DW. New aspects of the blood coagulation cascade, anticoagulants and vein thrombosis in Asia. Ann Acad Med Singapore 2002; 31: 685-696.
10. Eichinger S, et al. Determinants of plasma factor VIIa levels in humans. Blood 1995; 86: 3021-3025.
11. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
12. Broze GJ. The tissue factor pathway of coagulation: Factor VII, tissue factor, and tissue factor pathway inhibitor. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. New York: Churchill Livingstone, 1994: 349-377.
13. Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-6691.
14. Iijima K, Fukuda C, Nakamura K. Measurements of tissue factor-like activity in plasma of patients with DIG. Thromb Res 1991; 61: 29-38.
15. Butenas S, van', V, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272: 21527-21533.
16. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
17. Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation Factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 12337-12345.
18. Zur M, Nemerson Y. Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor. J Biol Chem 1980; 255: 5703-5707.
19. Repke D et al. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 1990; 87: 7623-7627.
20. Jesty J, Nêmerson Y. The pathways of blood coagulation. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. New York: McGraw-Hill, 1995: 1227-1238.
21. Pixley RA, Colemann RW. Factor XH: Hagemann factor. In: Lorand L, Mann KG, eds. Methods in Enzymology, Part A. San Diego: Academic, 1993: 51-64.
22. Mandle R jun., Kaplan AP. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 1977; 252: 6097-6104.
23. Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-1175.
24. Fujikawa K, Legaz ME, Kato H, Davie EW. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent). Biochemistry 1974; 13: 4508-4516.
25. Hultin MB, Nemerson Y. Activation of factor X by factors IXa and VIII; a specific assay for factor IXa in the presence of thrombin-activated factor VIII. Blood 1978; 52: 928-940.
26. Tans G, et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-2648.
27. Jackson CM. Physiology and biochemistry of prothrombin. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. New York: Churchill Livingstone, 1994: 397-438.
28. Kalafatis M, Swords NA, Rand MD, Mann KG. Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1994; 1227: 113-129.
29. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-10962.
30. Tracy PB et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74: 1221-1228.
31. Gailani D, Broze GJ jun. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912.
32. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature 1991; 353: 674-677.
33. Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229.
34. Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29: 177-188.
35. Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. Biochemistry 1991; 30: 934-941.
36. McDonagh J. Structure and function of factor XIII. In: Coleman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott, 1994: 301-313.
37. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem 1999; 274: 22862-22870.
38. Esmon CT, Esmon NL, Le Bonniec BF, Johnson AE. Protein C activation. Methods Enzymol 1993; 222: 359-385.
39. Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258: 12238-12242.
40. Broze GJ jun, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343.
41. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
42. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352.
43. Hockin MF, Kalafatis M, Shatos M, Mann KG. Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Aneriosder Thromb Vasc Biol 1997; 17: 2765-2775.
44. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-559.
45. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
46. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-2366.
47. Cawthern KM, et al. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-4592.
48. George JN. Platelets. Lancet 2000; 355: 1531-1439.
49. Deckmyn H, Vanhoorelbeke K, Peerlinck K. Inhibitory and activating human antiplatelet antibodies. Baillieres Clin Haematol 1998; 11: 343-359.
50. Rosing J, et al. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65: 319-332.
51. Walsh PN. Platelet coagulant activities and hemostasis: a hypothesis. Blood 1974; 43: 597-605.
52. Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 2002; 126: 133-146.
53. Marcus AJ. Platelets and their disorders. In: Ratnoff OC, Forbes CD, eds. Disorders of Hemostasis. Philadelphia, Pa: WB Saunders, 1996: 79-137.
54. Meyer D, Baumgartner HR. Role of von Willebrand factor in platelet adhesion to the subendothelium. Br J Haematol 1983; 54: 1-9.
55. Siedlecki CA, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
56. Tracy PR. Role of platelets and leukocytes in coagulation. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott, 2001: 575-596.
57. Ruggeri ZM, Savage B. Biological functions of von Willebrand factor. In: Ruggeri ZM, ed. Von Willebrand Factor and the Mechanisms of Platelet Function. Berlin: Springer-Verlag, 1998: 79-109.
58. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
59. Fukami MH, Holmsen H, Kowalski MA, Niewiarowski S. Platelet secretion. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Phladelphia, Pa: JB Lippincott Co, 2001: 561-574.
60. Peerschke EI. Platelet membrane glycoproteins. Functional characterization and clinical applications. Am J Clin Pathol 1992; 98: 455-463.
61. Zwaal RF, Comfurius P, Bevers EM. Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem Soc Trans 1993; 21: 248-253.
62. Zwaal RF. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978; 515: 163-205.
63. Zwaal RFA, Bevers EM, Comfurius P. Platelets and coagulation. In: Zwaal RFA, Hemker HC, eds. Blood Coagulation. New York: Elsevier Science Publishers, 1986: 141-169.
64. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213-226.
65. Tracy PB, Nesheim ME, Mann KG. Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem 1981; 256: 743-751.
66. Nelsestuen GL, Kisiel W, Di Scipio RG. Interaction of vitamin K dependent proteins with membranes. Biochemistry 1978; 17: 2134-2138.
67. Greenberg CS, Achyuthan KE, Fenton JW. Factor XIIIa formation promoted by complexing of alpha-thrombin, fibrin, and plasma factor XIII. Blood 1987;69: 867-871.
68. Lewis SD, Janus TJ, Lorand L, Shafer JA. Regulation of formation of factor XIIIa by its fibrin substrates. Biochemistry 1985; 24: 6772-6777.
69. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-7358.
70. Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-9425.
71. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 915-956.
72. Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. J Biol Chem 1975; 250: 388-395.
73. Shuman MA, Majerus PW. The measurement of thrombin in clotting blood by radioimmunoassay. J Clin Invest 1976; 58: 1249-1258.
74. Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67: 3-12.
75. Neuenschwander P, Jesty J. A comparison of phospholipid and platelets in the activation of human factor VIII by thrombin and factor Xa, and in the activation of factor X. Blood 1988; 72: 1761-1770.
76. Giddings JC, Bloom AL. Factor-V activation by thrombin and its role in prothrombin conversion. Br J Haematol 1975; 29: 349-364. g
77. Baruch D, Hemker HC, Lindhout T . Kinetics of thrombin-induced release and activation of platelet factor V. Eur J Biochem 1986; 154: 213-218.
78. Jesty J, Beltrami E, Willems G. Mathematical analysis of a proteolytic positive-feedback loop: dependence of lag time and enzyme yields on the initial conditions and kinetic parameters. Biochemistry 1993; 32: 6266-6274.
79. Rosenberg RD. Regulation of the hemostatic mechanism. In: Stamatoyannopoulos G, Nienhuis AW, Leder P, Majerus PW, eds. The Molecular Basis of Blood Diseases. Philadelphia: Saunders, 1987: 534-574.
80. Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984; 74: 1-6.
81. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746.
82. van', V, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 1997; 272: 4367-4377.
83. van', V, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 1997; 272: 7983-7994.
84. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709.
85. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505.
86. Kurachi K, Fujikawa K, Schmer G, Davie EW. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry 1976; 15: 373-377.
87. Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin. J Biol Chem 1975; 250: 8883-8838.
88. Stead N, Kaplan AP, Rosenberg RD. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976; 251: 6481-6488.
89. Jesty J. The kinetics of formation and dissociation of the bovine thrombin antithrombin III complex. J Biol Chem 1979; 254: 10044-10050.
90. Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17: 2649-2653.
91. Jesty J. The kinetics of inhibition of alpha-thrombin in human plasma. J Biol Chem 1986; 261: 10313-10318.
92. Jesty J. Measurement of the kinetics of inhibition of activated coagulation factor X in human plasma: the effect of plasma and inhibitor concentration. Anal Biochem 1986; 152: 402-411.
93. Tollefsen DM. Heparin cofactor II deficiency. Arch Pathol Lab Med 2002; 126: 1394-1400.
94. Rao LV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-651.
95. Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985; 66: 204-212.
96. Seegers WH, Novoa E, Henry RL, Hassouna HI. Relationship of 'new' vitamin K-dependent protein C and 'old' autoprorhrombin II-a. Thromb Res 1976; 8: 543-552.
97. Ehrlich HJ, et al. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-13035.
98. Ehrlich HJ, Keijer J, Preissner KT, Gebbink RK, Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 1991; 30: 1021-1028.
99. Whalen J, Tuman KJ. Monitoring hemostasis. Int Anesthesiol Clin 1996; 34: 195-213.
100. Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin Thromb Hemost 1999; 25: 407-418.
101. Miletich JP. Prothrombin time. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. New York: McGraw-Hill, 1995: L82-L84.
102. Kitchens CS. Prolonged activated partial thromboplastin time of unknown etiology: a prospective study of 100 consecutive cases referred for consultation. Am J Hematol 1988; 27: 38-45.
103. Miletich JP. Activated partial thromboplastin time. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. New York: McGraw-Hill, 1995: L85-L86.
104. Blackbeard, J. Full Blood Counts and Differential Counts on the Adiva 120. Hindley, N. MB046.R00. 2002. Department of Clinical Laboratory Sciences, University of Cape Town.
105. Miletich JP. Bleeding time. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. New York: McGraw-Hill, 1995: L111-L112.
106. Peterson P, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133: 134-139.
107. Miletich JP. Activated clotting time. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. New York: McGraw-Hill, 1995: L86.
108. Hindley, N. Platelet Aggregation. Williamson, A. C022.R01. 2003. Department of Clinical Laboratory Sciences, University of Cape Town.
109. Hindley, N. Antithrombin III. Williamson, A. C023. R01. 2002. Department of Clinical Laboratory Sciences, University of Cape Town.
110. Dade Behring. Enzygnost TAT micro. June 1998. 1998.
111. Hindley, N. D-Dimers (XDP). Williamson, A. C008. R01. 2003. Department of Clinical Laboratory Sciences, University of Cape Town.
112. Konrad C, Markl T, Schuepfer G, Gerber H, Tschopp M. The effects of in vitro hemodilution with gelatin, hydroxyethyl starch, and lactated Ringer's solution on markers of coagulation: an analysis using SONOCLOT. Anesth Analg 1999; 88: 483-488.
113. Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res 1994; 74: 335-346.
114. Steer PL, Krantz HB. Thromboelastography and Sonoclot analysis in the healthy parturient. J Clin Anesth 1993; 5: 419-424.
115. Ekback G, Schott U, Axelsson K, Carlberg M. Perioperative autotransfusion and functional coagulation analysis in total hip replacement. Acta Anaesthesiol Scand 1995; 39: 390-395.
116. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001; 12: 327-337.
117. Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Effects of progressive blood loss on coagulation as measured by thrombelastography. Anesth Analg 1987; 66: 856-863.
118. Nielsen VG, Geary BT, Baird MS. Evaluation of the contribution of platelets to clot strength by thromboelastography in rabbits: the role of tissue factor and cytochalasin D. AnesthAnalg 2000; 91: 35-39.
119. Oshita K, Az-ma T, Osawa Y, Yuge O. Quantitative measurement of thromboelastography as a function of platelet count. AnesthAnalg 1999; 89: 296-299.
120. Klein SM et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth Analg 2000; 91: 1091-1095.
121. Gibbs NM, Crawford GP, Michalopoulos N. Thrombelastographic patterns following abdominal aortic surgery. Anaesth Intensive Care 1994; 22: 534-538.
122. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth 1992; 69: 307-313.
123. Samama CM. Thromboelastography: the next step. Anesth Analg 2001; 92: 563-564.
124. Whitten CW, Greilich PE. Thromboelastography: past, present, and future. Anesthesiology 2000; 92: 1223-1225.
125. Zuckerman L, Cohen E, Vagher JP, Woodward E, Caprini JA. Comparison of thrombelastography with common coagulation tests. Thromb Haemost 1981; 46: 752-756.
126. Pivalizza EG, Henderson KL, Craig AL. Discrepancy between thromboelastography and prothrombin time. Anesthesiology 1996; 84: 1262.
127. KangYG et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-896.
128. Howland WS, Schweizer O, Gould P. A comparison of intraoperative measurements of coagulation. Anesth Analg 1974; 53: 6576-6563.
129. McNicol PL et al. Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thrombelastography. Anaesth Intensive Care 1994; 22: 659-665.
130. Chapin JW, Peters KR, Winslow J, Becker GL, Skinner H. Circulating heparin during liver transplantation. Transplant Proc 1993; 25: 1803.
131. Pivalizza EG, Abramson DC. Thromboelastography: another point of view. Anesth Analg 2001; 93: 517-518.
132. Davis CL, Chandler WL. Thromboelastography for the prediction of bleeding after transplant renal biopsy. J Am Soc Nephrol 1995; 6: 1250-1255.
133. Srinivasa V, Gilbertson LI, Bhavani-Shankar K. Thromboelastography: where is it and where is it heading? Int Anesthesiol Clin 2001; 39: 35-49.
134. Kaufmann CR, Dwyer KM, Crews JD, Dois SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42: 716-720.
135. Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989; 69: 69-75.
136. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993; 7: 410-415.
137. Martin P, Horkay F, Rajah SM, Walker DR. Monitoring of coagulation status using thrombelastography during paediatric open heart surgery. Int J Clin Monit Comput 1991; 8: 183-187.
138. Murray DJ et al. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997; 11: 24-28.
139. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001; 86: 575-578.
140. Spiess BD, et al. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit 1987; 3: 25-30.
141. Wong CA, Liu S, Glassenberg R. Comparison of thrombelastography with common coagulation tests in preeclamptic and healthy parturients. Reg Anesth 1995; 20: 521-527.
142. Orlikowski CE, et al. Thrombelastography changes in pre-eclampsia and eclampsia. Br J Anaesth 1996; 77: 157-161.
143. Mahla E, et al. Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery. Anesth Analg 2001; 92: 572-577.